<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>BioScreening - organic compounds for screening</title>
<link>http://www.bioscreening.com/index/</link>
<description>Directory  of companies supplying compounds for screening</description>
<generator>BBDMS 1.0.0</generator>
<managingEditor>info@bioscreening.com (Somebody)</managingEditor>
<webMaster>info@bioscreening.com (Somebody)</webMaster>
<pubDate>Fri, 09 May 2008 19:09:29 -0400</pubDate>
<lastBuildDate>Fri, 09 May 2008 19:09:29 -0400</lastBuildDate>
<language>en</language>
<copyright>Copyright by Somebody</copyright>
<item>
<title>Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates</title>
<link>http://www.bioscreening.net/2008/03/26/advances-in-cell-based-assays-offer-promise-for-the-discovery-of-new-drug-candidates/</link>
<description>
<![CDATA[ LONDON–(BUSINESS WIRE)–The drug discovery process has changed dramatically over the past decade and continues to evolve in response to new discoveries and technologies. There is also increasing demand to produce more drug candidates and […] ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Thu, 10 Apr 2008 11:15:00 -0400</pubDate>
</item>
<item>
<title>Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery</title>
<link>http://www.bioscreening.net/2008/04/09/spermatech-selects-evotec-as-partner-for-high-throughput-screening-and-lead-discovery-2/</link>
<description>
<![CDATA[ Hamburg, Germany | Oxford, UK | Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Thu, 10 Apr 2008 11:14:00 -0400</pubDate>
</item>
<item>
<title>Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec</title>
<link>http://www.bioscreening.net/2008/04/09/ono-enters-into-a-new-fragment-based-drug-discovery-agreement-with-evotec/</link>
<description>
<![CDATA[ Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Thu, 10 Apr 2008 11:13:00 -0400</pubDate>
</item>
<item>
<title>Advances in Synthetic Chemistry 2008</title>
<link>http://www.bioscreening.net/2008/01/07/advances-in-synthetic-chemistry-2008/</link>
<description>
<![CDATA[ Select Biosciences is proud to announce their first conference devoted to Advances in Synthetic Chemistry. The meeting will focus primarily on Flow Chemistry and Microwave-Assisted Organic Synthesis.
Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organizing a two day conference gathering some of the most influential researchers […] ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Mon, 07 Jan 2008 19:30:00 -0500</pubDate>
</item>
<item>
<title>Biological Drugs Spurring an Evolution in Injectable Drug Delivery</title>
<link>http://www.bioscreening.net/2008/01/03/biological-drugs-spurring-an-evolution-in-injectable-drug-delivery/</link>
<description>
<![CDATA[ The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace […] ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Wed, 02 Jan 2008 19:29:00 -0500</pubDate>
</item>
</channel>
</rss>
